Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy
Figure 1
(a) show overall survival curve grouped by ER, PR, and Her 2; (b) show disease-free survival curve grouped by ER, PR, and HER2; (c) show overall survival curve grouped by ER, PR, HER 2, and Ki67; (d) show disease-free survival curve grouped by ER, PR, Ki67, and HER2.